Your browser doesn't support javascript.
loading
Trend of Bronchial Hyperresponsiveness to Methacholine as a Cost Predictor of Mild-to-Moderate Asthma: A Twelve-Month Survey in Teenagers.
Dal Negro, Roberto W; Turco, Paola; Povero, Massimiliano.
Afiliación
  • Dal Negro RW; National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology-CESFAR, 37124 Verona, Italy.
  • Turco P; National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology-CESFAR, 37124 Verona, Italy.
  • Povero M; AdRes Health Economics and Outcomes Research, 10121 Turin, Italy.
Children (Basel) ; 10(12)2023 Nov 29.
Article en En | MEDLINE | ID: mdl-38136078
ABSTRACT
Bronchial asthma is characterized by variable airflow obstruction, airway inflammation, and bronchial hyperresponsiveness (BHR) to non-specific stimuli. The role of underlying airway inflammation and of related long-lasting BHR has been suboptimally investigated in teenagers with mild-to-moderate asthma, as has the corresponding economic impact over time. The aim of the present study was to calculate the cost of mild-to-moderate atopic asthma in teenagers arising from their degree of persisting BHR over a twelve-month period.

METHODS:

Patients aged 12-18 years with mild-to-moderate symptoms treated with fluticasone fumarate/vilanterol 92/22 mcg daily were retrospectively followed for 12 months. Usual spirometric parameters, BHR to methacholine (MCh), and resource consumption (visits, hospitalizations, systemic steroids and/or antibiotics courses, school days off) were assessed at recruitment (the index date) and after 6 and 12 months. Adherence to treatment was also calculated. The cost of asthma was calculated based on Italian tariffs and published papers. The trend over time in BHR and the association between response to MCh and total cost were investigated by using regression models adjusted for repeated measures.

RESULTS:

106 teenagers (53 males, age 15.9 ± 1.6 years) were investigated. The annual cost of asthma proved significantly related to the BHR trend every increment of a factor 10 in the response to MCh was associated with a saving of EUR 184.90 (95% CI -305.89 to -63.90). BHR was progressively optimized after 6 and 12 months in relation to the patients' compliance to treatment (≥70% of prescribed inhalation doses).

CONCLUSIONS:

the usual spirometric parameters are largely insufficient to reflect the effects of underlying persistent inflammation in milder forms of asthma in teenagers. In terms of clinical governance, the periodic assessment of non-specific BHR is the appropriate procedure from this point of view. Non-specific BHR proves a reliable procedure for predicting and monitoring the economic impact of mild-to-moderate asthma in teenagers over time.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Children (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Children (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Italia